Aura Biosciences (AURA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$0.37
- Surprise
- —
- Score today
- 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Aura Biosciences May Offer Securities Up To $500M Aggregate; May Sell Up To $200M Common Stock Under Sales Agreement Wit — benzinga, 2026-08-11
- HC Wainwright & Co. Maintains Buy on Aura Biosciences, Lowers Price Target to $18 — benzinga, 2026-08-11
- Aura Biosciences Q2 EPS $(0.48) Misses $(0.38) Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates AURA Sell at 5.5/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-12.
What argues against it
- Concentration risk — Pipeline: bel-sar
- Quality below floor (1.6 < 4.0)
- Value-trap signals (2/5): High leverage (D/E 5.2), Material insider selling (33 sells, 20.79% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.00
- Price target
- $14.44
- Stop
- $6.39
- Upside to target
- +106.3%
- Reward-to-risk
- 11.3:1
Risk check: RSI 26 — a level conventionally read as oversold; trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
AURA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $717.6M
- P/E (fwd)
- -3.4
- 52-week range
- $4.73–$9.54
- Off 52-week high
- 26.6%
- RSI (14)
- 26
- Volume vs avg
- 1.88×
- Score today
- 5.5/10